Investigational drug · Phase 2
Briquilimab
Also called: JSP191
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Spontaneous Urticaria.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
9
Any phase or sponsor naming "Briquilimab"
First trial start
2023
Nov 29, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Briquilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Spontaneous Urticaria
Approved drugs for the same conditions: Chronic hives (urticaria) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Briquilimab" as an intervention, largest first.
Jasper Therapeutics, Inc.Industry
NCT06162728 · 87 participants · Start Nov 29, 2023 · Primary completion Jul 8, 2026
Drug: Briquilimab · For: Chronic Spontaneous Urticaria
Sites: Birmingham, Alabama; Little Rock, Arkansas; San Diego, California · 23 sites in all
Jasper Therapeutics, Inc.Industry
NCT06736262 · 67 participants · Start Nov 26, 2024 · Primary completion Jul 21, 2026
Drug: Briquilimab · For: Urticaria Chronic
Sites: Birmingham, Alabama; Little Rock, Arkansas; San Diego, California · 19 sites in all
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-ThalassemiaActive, not recruiting
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT05357482 · 40 participants · Start May 12, 2022 · Primary completion Jan 31, 2026
Drug: Hydroxyurea; briquilimab and 4 more · For: Sickle Cell Anemia; Beta Thalassemia
Sites: Bethesda, Maryland
Jasper Therapeutics, Inc.Industry
NCT06353971 · 27 participants · Start Mar 18, 2024 · Primary completion Jul 31, 2025
Drug: Briquilimab · For: Chronic Inducible Urticaria
Sites: Berlin, Germany; Dresden, Germany; Lübeck, Germany · 5 sites in all
Porteus, Matthew, MDAcademic, hospital or other
NCT04784052 · 18 participants (planned) · Start Dec 7, 2021 · Primary completion Dec 2027
Drug: JSP191; Depleted Stem Cell Transplant and 4 more · For: Fanconi Anemia
Sites: Stanford, California
Jasper Therapeutics, Inc.Industry
NCT06592768 · 17 participants · Start Nov 26, 2024 · Primary completion Aug 11, 2025
Drug: Briquilimab · For: Allergic Asthma
Sites: Calgary, Canada; Edmonton, Canada; Vancouver, Canada · 6 sites in all
- Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 DeficiencyActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05907746 · 13 participants · Start Nov 29, 2023 · Primary completion Oct 16, 2025
Drug: Mycophenolate Mofetil; Tacrolimus and 4 more · For: GATA2; Immunodeficiency
Sites: Bethesda, Maryland
- Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ FunctionActive, not recruiting
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT06145282 · 6 participants · Start Dec 28, 2023 · Primary completion Oct 27, 2025
Drug: Briquilimab; Filgrastim and 3 more · For: Sickle Cell Disease
Sites: Bethesda, Maryland
Jasper Therapeutics, Inc.Industry
NCT05903274 · 6 participants · Start Jun 19, 2023 · Primary completion Oct 21, 2024
Drug: JSP191 · For: Lower-risk Myelodysplastic Syndrome
Sites: Hollywood, Florida; Tampa, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Beyond Omalizumab: Emerging Biologic and Small Molecule Therapies in Chronic Spontaneous Urticaria.
Kaur S, Kumaran MS, Singh S, et al. · Clin Exp Allergy 2026
- Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.
Andrzejczak K, Witkowski W, Górka-Dynysiewicz J, et al. · Pharmaceutics 2026
- Mast cell depletion and repopulation dynamics define briquilimab efficacy in a mouse model of allergic asthma.
Yu M, Ratia S, Kattel S, et al. · J Allergy Clin Immunol 2026
- Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.
Muffly L, Lee CJ, Gandhi A, et al. · Blood 2026
- Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human-Mouse KIT.
Kwon HS, Lee SE, Sharma A, et al. · Allergy 2026
- Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in nonhuman primates.
Lee SE, Bouzid H, Kwan C, et al. · J Allergy Clin Immunol 2025
Also in development for Chronic Spontaneous Urticaria
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- JYB1904RPT904, ozureprubartPhase 35 trials
Jemincare · Chronic Spontaneous Urticaria, Perennial Allergic Rhinitis, Immune System Diseases
- AK139Phase 26 trials
Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
- BLU-808Phase 22 trials
Blueprint Medicines Corporation · Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Allergic Rhinoconjunctivitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.